Mayo Clinic Laboratory and Pathology Research Roundup: May 22

By Kelley Luedke • May 22, 2017

Share this:

The Research Roundup provides an overview of the past week’s research from Mayo Medical Laboratories consultants, including featured abstracts and complete list of published studies and reviews.

Featured Abstract

Management of Diffuse Low-Grade Gliomas in Adults: Use of Molecular Diagnostics

Diffuse WHO grade II gliomas are histologically and genetically heterogeneous. The 2016 WHO classification redefines grade II gliomas with respect to morphological and molecular tumor alterations: grade II oligodendrogliomas are defined by the presence of whole-arm codeletion in chromosomal arms 1p/19q, whereas isocitrate dehydrogenase (IDH) mutations define subclasses of astrocytoma. Although histological grade remains useful, the prognoses of patients with glioma are more tightly associated with molecular alterations than with grade, and chromosomal and gene array technologies are becoming increasingly beneficial in understanding tumor genetic heterogeneity. The indolent nature of the disease often creates subtle neurological symptoms that can be overlooked or misunderstood, resulting in delayed diagnosis. Seizures often herald the diagnosis, especially in patients who have IDH mutations, which are associated with an increased production of 2-hydroxyglutarate. Treatment paradigms have shifted, owing to new diagnostic criteria and new clinical trial evidence. Patients benefit more from chemoradiation than radiation alone, especially those with tumor IDH1 Arg132His mutations; gross total resection of the tumor, including tumous with IDH mutations, is associated with prolonged survival. Initial observation remains appropriate in patients whose rate of disease growth is not yet completely defined; such patients could include those with completely resected disease and those with 1p/19q codeleted tumors. The study was published in Nature Reviews Neurology.

Published to PubMed This Week

• In-Depth Clinico-Pathological Examination of RNA Foci in a Large Cohort of C9ORF72 Expansion Carriers
  Acta Neuropathologica
• Evaluation of ACMG-Guideline-Based Variant Classification of Cancer Susceptibility and Non-Cancer-Associated Genes in Families Affected by Breast Cancer
  American Journal of Human Genetics
  
• Human DBR1 Modulates the Recycling of snRNPs to Affect Alternative RNA Splicing and Contributes to the Suppression of Cancer Development
  Oncogene
• The Presence of Interleukin-13 at Pancreatic ADM/PanIN Lesions Alters Macrophage Populations and Mediates Pancreatic Tumorigenesis
  Cell Reports
• Usefulness for Predicting Cardiac Events After Orthotopic Liver Transplantation of Myocardial Perfusion Imaging and Dobutamine Stress Echocardiography Preoperatively
  American Journal of Cardiology
• Morphologic Subtypes of Hepatocellular Carcinoma
  Gastroenterology Clinics of North America
• Lymphoma Classification Update: T-Cell Lymphomas, Hodgkin Lymphomas, and Histiocytic/Dendritic Cell Neoplasms
  Cancer Chemotherapy Pharmacology
• Cystadenoma of the Rete Testis in a Patient with Von-Hippel Lindau Disease
  Urology
• Bordetella Parapertussis Outbreak in Southeastern Minnesota and the United States, 2014
  Medicine
• Radiologic-Pathologic Correlation: Acellular Dermal Matrix (Alloderm^®) Used in Breast Reconstructive Surgery
  Journal of Clinical Imaging Science

Kelley Luedke

Kelley Luedke is a Marketing Channel Manager at Mayo Clinic Laboratories. She is the principle editor and writer of Insights and leads social media and direct marketing strategy. Kelley has worked at Mayo Clinic since 2013. Outside of work, you can find Kelley running, traveling, playing with her kitty, and exploring new foods.